- Home
- LBTYA vs ACAD Comparison
LBTYA vs ACAD Comparison
Compare LBTYA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYA
- ACAD
- Stock Information
- Founded
- LBTYA 2004
- ACAD 1993
- Country
- LBTYA Bermuda
- ACAD United States
- Employees
- LBTYA N/A
- ACAD N/A
- Industry
- LBTYA Cable & Other Pay Television Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYA Telecommunications
- ACAD Health Care
- Exchange
- LBTYA Nasdaq
- ACAD Nasdaq
- Market Cap
- LBTYA 4.1B
- ACAD 4.3B
- IPO Year
- LBTYA N/A
- ACAD 2004
- Fundamental
- Price
- LBTYA $11.78
- ACAD $24.20
- Analyst Decision
- LBTYA Buy
- ACAD Buy
- Analyst Count
- LBTYA 5
- ACAD 21
- Target Price
- LBTYA $14.96
- ACAD $29.30
- AVG Volume (30 Days)
- LBTYA 1.7M
- ACAD 1.9M
- Earning Date
- LBTYA 10-30-2025
- ACAD 11-05-2025
- Dividend Yield
- LBTYA N/A
- ACAD N/A
- EPS Growth
- LBTYA N/A
- ACAD 615.00
- EPS
- LBTYA N/A
- ACAD 1.33
- Revenue
- LBTYA $4,633,000,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- LBTYA $10.21
- ACAD $14.01
- Revenue Next Year
- LBTYA $1.04
- ACAD $11.72
- P/E Ratio
- LBTYA N/A
- ACAD $18.30
- Revenue Growth
- LBTYA 81.79
- ACAD 14.41
- 52 Week Low
- LBTYA $9.03
- ACAD $13.40
- 52 Week High
- LBTYA $21.56
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- LBTYA 59.01
- ACAD 46.49
- Support Level
- LBTYA $11.73
- ACAD $23.34
- Resistance Level
- LBTYA $12.01
- ACAD $24.87
- Average True Range (ATR)
- LBTYA 0.27
- ACAD 0.82
- MACD
- LBTYA -0.04
- ACAD -0.25
- Stochastic Oscillator
- LBTYA 63.10
- ACAD 25.98
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.